{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T01:45:45Z","timestamp":1783647945086,"version":"3.55.0"},"reference-count":264,"publisher":"FapUNIFESP (SciELO)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arq Bras Endocrinol Metab"],"published-print":{"date-parts":[[2014,10]]},"abstract":"<jats:p>Introdu\u00e7\u00e3o O carcinoma medular de tireoide (CMT) origina-se das c\u00e9lulas parafoliculares da tireoide e corresponde a 3-4% das neoplasias malignas da gl\u00e2ndula. Aproximadamente 25% dos casos de CMT s\u00e3o heredit\u00e1rios e decorrentes de muta\u00e7\u00f5es ativadoras no proto-oncogene RET (REarranged during Transfection). O CMT \u00e9 uma neoplasia de curso indolente, com taxas de sobrevida dependentes do est\u00e1dio tumoral ao diagn\u00f3stico. Este artigo descreve diretrizes baseadas em evid\u00eancias cl\u00ednicas para o diagn\u00f3stico, tratamento e seguimento do CMT. Objetivo O presente consenso, elaborado por especialistas brasileiros e patrocinado pelo Departamento de Tireoide da Sociedade Brasileira de Endocrinologia e Metabologia, visa abordar o diagn\u00f3stico, tratamento e seguimento dos pacientes com CMT, de acordo com as evid\u00eancias mais recentes da literatura. Materiais e m\u00e9todos: Ap\u00f3s estrutura\u00e7\u00e3o das quest\u00f5es cl\u00ednicas, foi realizada busca das evid\u00eancias dispon\u00edveis na literatura, inicialmente na base de dados do MedLine-PubMed e posteriormente nas bases Embase e SciELO \u2013 Lilacs. A for\u00e7a das evid\u00eancias, avaliada pelo sistema de classifica\u00e7\u00e3o de Oxford, foi estabelecida a partir do desenho de estudo utilizado, considerando-se a melhor evid\u00eancia dispon\u00edvel para cada quest\u00e3o. Resultados Foram definidas 11 quest\u00f5es sobre o diagn\u00f3stico, 8 sobre o tratamento cir\u00fargico e 13 quest\u00f5es abordando o seguimento do CMT, totalizando 32 recomenda\u00e7\u00f5es. Como um todo, o artigo aborda o diagn\u00f3stico cl\u00ednico e molecular, o tratamento cir\u00fargico inicial, o manejo p\u00f3s-operat\u00f3rio e as op\u00e7\u00f5es terap\u00eauticas para a doen\u00e7a metast\u00e1tica. Conclus\u00f5es O diagn\u00f3stico de CMT deve ser suspeitado na presen\u00e7a de n\u00f3dulo tireoidiano e hist\u00f3ria familiar de CMT e\/ou associa\u00e7\u00e3o com feocromocitoma, hiperparatireoidismo e\/ou fen\u00f3tipo sindr\u00f4mico caracter\u00edstico, como ganglioneuromatose e habitus marfanoides. A pun\u00e7\u00e3o aspirativa por agulha fina do n\u00f3dulo, a dosagem de calcitonina s\u00e9rica e o exame anatomopatol\u00f3gico podem contribuir na confirma\u00e7\u00e3o do diagn\u00f3stico. A cirurgia \u00e9 o \u00fanico tratamento que oferece a possibilidade de cura. As op\u00e7\u00f5es de tratamento da doen\u00e7a metast\u00e1tica ainda s\u00e3o limitadas e restritas ao controle da doen\u00e7a. Uma avalia\u00e7\u00e3o p\u00f3s-cir\u00fargica criteriosa para a identifica\u00e7\u00e3o de doen\u00e7a residual ou recorrente \u00e9 fundamental para definir o seguimento e a conduta terap\u00eautica subsequente.<\/jats:p>","DOI":"10.1590\/0004-2730000003427","type":"journal-article","created":{"date-parts":[[2014,10,29]],"date-time":"2014-10-29T18:27:49Z","timestamp":1414607269000},"page":"667-700","source":"Crossref","is-referenced-by-count":24,"title":["Diagn\u00f3stico, tratamento e seguimento do carcinoma medular de tireoide: recomenda\u00e7\u00f5es do Departamento de Tireoide da Sociedade Brasileira de Endocrinologia e Metabologia"],"prefix":"10.1590","volume":"58","author":[{"given":"Ana Luiza","family":"Maia","sequence":"first","affiliation":[{"name":"Universidade Federal do Rio Grande do Sul, Brasil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debora R.","family":"Siqueira","sequence":"additional","affiliation":[{"name":"Universidade Federal do Rio Grande do Sul, Brasil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco A. V.","family":"Kulcsar","sequence":"additional","affiliation":[{"name":"Universidade de S\u00e3o Paulo, Brasil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfio J.","family":"Tincani","sequence":"additional","affiliation":[{"name":"Universidade Estadual de Campinas, Brasil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glaucia M. F. S.","family":"Mazeto","sequence":"additional","affiliation":[{"name":"Universidade Estadual Paulista J\u00falio de Mesquita Filho, Brasil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lea M. Z.","family":"Maciel","sequence":"additional","affiliation":[{"name":"Universidade de S\u00e3o Paulo, Brasil"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"530","reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.1001\/jama.295.18.2164","article-title":"Increasing incidence of thyroid cancer in the United States, 1973-2002","volume":"295","author":"Davies L","year":"2006","journal-title":"JAMA"},{"key":"ref2","first-page":"137","article-title":"Medullary thyroid carcinoma: clinical and oncological features and treatment","volume":"48","author":"Punales MK","year":"2004","journal-title":"Arq Bras Endocrinol Metabol"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"3149","DOI":"10.1210\/jc.2013-1204","article-title":"Multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma: an update","volume":"98","author":"Wells SA","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1093\/hmg\/3.2.237","article-title":"Point mutation within the tyrosine kinase domain of the RET proto-oncogene in multiple endocrine neoplasia type 2B and related sporadic tumours","volume":"3","author":"Eng C","year":"1994","journal-title":"Hum Mol Genet"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1677\/ERC-09-0312","article-title":"The RET polymorphic allele S836S is associated with early metastatic disease in patients with hereditary or sporadic medullary thyroid carcinoma","volume":"17","author":"Siqueira DR","year":"2010","journal-title":"Endocr Relat Cancer"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1210\/jcem.85.2.6556","article-title":"Preoperative calcitonin levels are predictive of tumor size and postoperative calcitonin normalization in medullary thyroid carcinoma. Groupe d\u2019Etudes des Tumeurs a Calcitonine (GETC)","volume":"85","author":"Cohen R","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1210\/jc.2004-1836","article-title":"Prospects of remission in medullary thyroid carcinoma according to basal calcitonin level","volume":"90","author":"Machens A","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1097\/00000658-199906000-00016","article-title":"Patterns of nodal metastases in palpable medullary thyroid carcinoma: recommendations for extent of node dissection","volume":"229","author":"Moley JF","year":"1999","journal-title":"Ann Surg"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1210\/jc.2002-021713","article-title":"Rationale for central and bilateral lymph node dissection in sporadic and hereditary medullary thyroid cancer","volume":"88","author":"Scollo C","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"4185","DOI":"10.1210\/jc.2007-1211","article-title":"Imaging medullary thyroid carcinoma with persistent elevated calcitonin levels","volume":"92","author":"Giraudet AL","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1089\/thy.1998.8.517","article-title":"Medullary thyroid carcinoma: clinical features and long-term follow-up of seventy-eight patients treated between 1969 and 1986","volume":"8","author":"Girelli ME","year":"1998","journal-title":"Thyroid"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1002\/cncr.22244","article-title":"Prognosis of medullary thyroid carcinoma: demographic, clinical, and pathologic predictors of survival in 1252 cases","volume":"107","author":"Roman S","year":"2006","journal-title":"Cancer"},{"key":"ref13","series-title":"Levels of Evidence and Grades of Recommendations \u2013 Oxford Centre for Evidence-Based Medicine","year":"2014"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1590\/S0004-27302013000400002","article-title":"Thyroid nodules and differentiated thyroid cancer: update on the Brazilian consensus","volume":"57","author":"Ros\u00e1rio PW","year":"2013","journal-title":"Arq Bras Endocrinol Metabol"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1097\/00005792-196809000-00001","article-title":"Study of a kindred with pheochromocytoma, medullary thyroid carcinoma, hyperparathyroidism and Cushing\u2019s disease: multiple endocrine neoplasia, type 2","volume":"47","author":"Steiner AL","year":"1968","journal-title":"Medicine"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1002\/(SICI)1097-0339(200006)22:6<351::AID-DC5>3.0.CO;2-T","article-title":"Cytologic diagnosis of medullary carcinoma of the thyroid gland","volume":"22","author":"Papaparaskeva K","year":"2000","journal-title":"Diagn Cytopathol"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"920","DOI":"10.4158\/EP13143.OR","article-title":"Fine needle aspiration and medullary thyroid carcinoma: the risk of inadequate preoperative evaluation and initial surgery when relying upon FNAB cytology alone","volume":"19","author":"Essig GF","year":"2013","journal-title":"Endocr Pract"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1002\/jso.20269","article-title":"Preoperative diagnosis of medullary thyroid carcinoma: fine needle aspiration cytology as compared with serum calcitonin measurement","volume":"91","author":"Bugalho MJ","year":"2005","journal-title":"J Surg Oncol"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1159\/000326191","article-title":"Medullary thyroid carcinoma: pitfalls in diagnosis by fine needle aspiration cytology and relationship of cytomorphology to RET proto-oncogene mutations","volume":"49","author":"Chang TC","year":"2005","journal-title":"Acta Cytol"},{"issue":"1","key":"ref20","article-title":"FNA of misclassified primary malignant neoplasms of the thyroid: impact on clinical management","volume":"6","author":"Shah SS","year":"2009","journal-title":"Cytojournal"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/(SICI)1097-0142(19981025)84:5<295::AID-CNCR5>3.0.CO;2-J","article-title":"Medullary carcinoma of the thyroid: accuracy of diagnosis of fine-needle aspiration cytology","volume":"84","author":"Forrest CH","year":"1998","journal-title":"Cancer"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1210\/jc.2007-0326","article-title":"Calcitonin measurement in wash-out fluid from fine needle aspiration of neck masses in patients with primary and metastatic medullary thyroid carcinoma","volume":"92","author":"Boi F","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1590\/S0004-27302009000400016","article-title":"Identification of occult metastases of medullary thyroid carcinoma by calcitonin measurement in washout fluid from fine needle aspiration of cervical lymph node","volume":"53","author":"Siqueira D","year":"2009","journal-title":"Arq Bras Endocrinol Metabol"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/cen.12234","article-title":"Calcitonin measurement in aspiration needle washout fluids has higher sensitivity than cytology in detecting medullary thyroid cancer: a retrospective multicentre study","volume":"80","author":"Trimboli P","year":"2014","journal-title":"Clin Endocrinol"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1007\/BF02471717","article-title":"The significance of immunochemically staining calcitonin and CEA in fine-needle aspiration biopsy materials from medullary carcinoma of the thyroid","volume":"19","author":"Takeichi N","year":"1989","journal-title":"Jpn J Surg"},{"key":"ref26","first-page":"951","article-title":"Preoperative diagnosis of medullary thyroid carcinoma by RT-PCR using RNA extracted from leftover cells within a needle used for fine needle aspiration biopsy","volume":"84","author":"Takano T","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"key":"ref27","first-page":"1797","article-title":"Scanning electron microscopy of the human thyroid gland and its disorders","volume":"1","author":"Nesland JM","year":"1987","journal-title":"Scanning Microsc"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1159\/000328374","article-title":"Three-dimensional cytomorphology in fine needle aspiration biopsy of medullary thyroid carcinoma","volume":"45","author":"Chang TC","year":"2001","journal-title":"Acta Cytol"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1210\/jc.2006-1590","article-title":"Predictive value of serum calcitonin levels for preoperative diagnosis of medullary thyroid carcinoma in a cohort of 5817 consecutive patients with thyroid nodules","volume":"92","author":"Costante G","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1055\/s-2004-815727","article-title":"Calcitonin measurement to detect medullary thyroid carcinoma in nodular goiter: German evidence-based consensus recommendation","volume":"112","author":"Karges W","year":"2004","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1111\/cen.12001","article-title":"Groupe des Tumeurs Endocrines. Is basal ultrasensitive measurement of calcitonin capable of substituting for the pentagastrin-stimulation test?","volume":"78","author":"Pina G","year":"2013","journal-title":"Clin Endocrinol"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1210\/jc.2011-2033","article-title":"Comparison of calcium and pentagastrin tests for the diagnosis and follow-up of medullary thyroid cancer","volume":"97","author":"Colombo C","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1210\/jc.2013-4088","article-title":"Refining calcium test for the diagnosis of medullary thyroid cancer: cutoffs, procedures, and safety","volume":"99","author":"Mian C","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1056\/NEJM197010222831702","article-title":"Immunoassay of human calcitonin","volume":"283","author":"Tashijan AH","year":"1970","journal-title":"N Engl J Med"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1210\/jc.2003-030709","article-title":"Frequency and relevance of elevated calcitonin levels in patients with neoplastic and nonneoplastic thyroid disease and in healthy subjects","volume":"89","author":"Karanikas G","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1373\/clinchem.2004.040501","article-title":"Prevalence of heterophilic antibody interference in eight automated tumor marker immunoassays","volume":"51","author":"Preissner CM","year":"2005","journal-title":"Clin Chem"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1089\/thy.2012.0564","article-title":"influence of chronic autoimmune thyroiditis and papillary thyroid cancer on serum calcitonin levels","volume":"23","author":"Rosario PW","year":"2013","journal-title":"Thyroid"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1210\/jc.2005-1429","article-title":"\u201cHook effect\u201d in calcitonin immunoradiometric assay in patients with metastatic medullary thyroid carcinoma: case report and review of the literature","volume":"91","author":"Leboeuf R","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1089\/thy.2007.0231","article-title":"Normal perioperative serum calcitonin levels in patients with advanced medullary thyroid carcinoma: case report and review of the literature","volume":"18","author":"Dora JM","year":"2008","journal-title":"Thyroid"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1002\/hed.21228","article-title":"Benefit of measuring basal serum calcitonin to detect medullary thyroid carcinoma in a Danish population with a high prevalence of thyroid nodules","volume":"32","author":"Hasselgren M","year":"2010","journal-title":"Head Neck"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/BF03344126","article-title":"Value of routine measurement of serum calcitonin concentrations in patients with nodular thyroid disease: a multicenter study","volume":"29","author":"Papi G","year":"2006","journal-title":"J Endocrinol Invest"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1210\/jc.2003-030550","article-title":"Impact of routine measurement of serum calcitonin on the diagnosis and outcome of medullary thyroid cancer: experience in 10,864 patients with nodular thyroid disorders","volume":"89","author":"Elisei R","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1210\/jc.2006-2735","article-title":"Editorial: calcitonin determination in patients with nodular thyroid disease","volume":"92","author":"Borget I","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1210\/jc.2007-2496","article-title":"Calcitonin measurement in the evaluation of thyroid nodules in the United States: a cost-effectiveness and decision analysis","volume":"93","author":"Cheung K","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/j.1365-2265.1995.tb02662.x","article-title":"Prevalence of sporadic medullary thyroid carcinoma: the importance of routine measurement of serum calcitonin in the diagnostic evaluation of thyroid nodules","volume":"42","author":"Rieu M","year":"1995","journal-title":"Clin Endocrinol"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1089\/thy.1999.9.579","article-title":"Evaluation of routine basal serum calcitonin measurement for early diagnosis of medullary thyroid carcinoma in seven hundred seventy-three patients with nodular goiter","volume":"9","author":"Ozgen AG","year":"1999","journal-title":"Thyroid"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1089\/10507250150500694","article-title":"Routine measurement of serum calcitonin is useful for early detection of medullary thyroid carcinoma in patients with nodular thyroid diseases","volume":"11","author":"Hahm JR","year":"2001","journal-title":"Thyroid"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1210\/jc.2010-2359","article-title":"Clinical review: Incidentally discovered medullary thyroid cancer: diagnostic strategies and treatment","volume":"96","author":"Ahmed SR","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/j.beem.2008.09.008","article-title":"Routine serum calcitonin measurement in the evaluation of thyroid nodules","volume":"22","author":"Elisei R","year":"2008","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1210\/jcem.82.5.3949","article-title":"Routine measurement of plasma calcitonin in nodular thyroid diseases","volume":"82","author":"Vierhapper H","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"key":"ref51","first-page":"826","article-title":"Routine measurement of serum calcitonin in nodular thyroid diseases allows the preoperative diagnosis of unsuspected sporadic medullary thyroid carcinoma","volume":"78","author":"Pacini F","year":"1994","journal-title":"J Clin Endocrinol Metab"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"201S","DOI":"10.1111\/j.1365-2265.1976.tb03828.x","article-title":"Evidence for secretion of vasoactive intestinal peptide by tumours of pancreas, adrenal medulla, thyroid and lung: support for the unifying APUD concept","volume":"5","author":"Said SI","year":"1976","journal-title":"Clin Endocrinol"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"25","DOI":"10.3109\/01913128509141506","article-title":"Medullary carcinoma of the thyroid gland: an immunocytochemical study","volume":"8","author":"Holm R","year":"1985","journal-title":"Ultrastruct Pathol"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.clon.2010.05.002","article-title":"Medullary thyroid carcinoma","volume":"22","author":"Pacini F","year":"2010","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1001\/archsurg.142.3.289","article-title":"Abnormal carcinoembryonic antigen levels and medullary thyroid cancer progression: a multivariate analysis","volume":"142","author":"Machens A","year":"2007","journal-title":"Arch Surg"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1210\/jc.2009-2368","article-title":"Biomarker-based risk stratification for previously untreated medullary thyroid cancer","volume":"95","author":"Machens A","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"ref57","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/BF03343959","article-title":"Ultrasonography: is it useful in the diagnosis of cancer in thyroid nodules?","volume":"25","author":"Peccin S","year":"2002","journal-title":"J Endocrinol Invest"},{"key":"ref58","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1089\/thy.2004.14.953","article-title":"Thyroid nodule shape and prediction of malignancy","volume":"14","author":"Alexander EK","year":"2004","journal-title":"Thyroid"},{"key":"ref59","first-page":"105","article-title":"Ultrasonographic evaluation of thyroid nodules: comparison with cytologic and histologic diagnosis","volume":"48","author":"Tomimori EK","year":"2004","journal-title":"Arq Bras Endocrinol Metabol"},{"key":"ref60","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1055\/s-2002-36546","article-title":"Role of conventional ultrasound and color Doppler sonography in the diagnosis of medullary thyroid carcinoma","volume":"110","author":"Saller B","year":"2002","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1148\/radiology.162.1.3538147","article-title":"Medullary thyroid carcinoma: role of high-resolution US","volume":"162","author":"Gorman B","year":"1987","journal-title":"Radiology"},{"key":"ref62","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/S0039-6060(03)00424-0","article-title":"Role of preoperative ultrasonography in the surgical management of patients with thyroid cancer","volume":"134","author":"Kouvaraki MA","year":"2003","journal-title":"Surgery"},{"key":"ref63","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1002\/lary.21227","article-title":"Efficacy of preoperative neck ultrasound in the detection of cervical lymph node metastasis from thyroid cancer","volume":"121","author":"Hwang HS","year":"2011","journal-title":"Laryngoscope"},{"key":"ref64","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1007\/s00268-008-9588-7","article-title":"Diagnostic accuracy of CT and ultrasonography for evaluating metastatic cervical lymph nodes in patients with thyroid cancer","volume":"32","author":"Ahn JE","year":"2008","journal-title":"World J Surg"},{"key":"ref65","first-page":"1596","article-title":"Low frequency of ras gene mutations in neuroblastomas, pheochromocytomas, and medullary thyroid cancers","volume":"51","author":"Moley JF","year":"1991","journal-title":"Cancer Res"},{"key":"ref66","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1002\/(SICI)1097-0142(20000301)88:5<1139::AID-CNCR26>3.0.CO;2-Z","article-title":"Medullary thyroid carcinoma: clinical characteristics, treatment, prognostic factors, and a comparison of staging systems","volume":"88","author":"Kebebew E","year":"2000","journal-title":"Cancer"},{"key":"ref67","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1002\/1097-0142(19890315)63:6<1196::AID-CNCR2820630626>3.0.CO;2-O","article-title":"Clinical characteristics in sporadic and familial medullary thyroid carcinoma. A nationwide study of 249 patients in Sweden from 1959 through 1981","volume":"63","author":"Bergholm U","year":"1989","journal-title":"Cancer"},{"key":"ref68","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/S0039-6060(03)00408-2","article-title":"Medullary thyroid carcinoma: results of a standardized surgical approach in a contemporary series of 80 consecutive patients","volume":"134","author":"Yen TW","year":"2003","journal-title":"Surgery"},{"key":"ref69","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1007\/BF03346458","article-title":"Degree of catecholamine hypersecretion is the most important determinant of intra-operative hemodynamic outcomes in pheochromocytoma","volume":"32","author":"Kramer CK","year":"2009","journal-title":"J Endocrinol Invest"},{"key":"ref70","first-page":"751","article-title":"Pheochromocytoma","volume":"48","author":"Pereira MA","year":"2004","journal-title":"Arq Bras Endocrinol Metabol"},{"key":"ref71","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S0140-6736(05)67139-5","article-title":"Phaeochromocytoma","volume":"366","author":"Lenders JW","year":"2005","journal-title":"Lancet"},{"key":"ref72","doi-asserted-by":"crossref","first-page":"3999","DOI":"10.1210\/jc.2005-0064","article-title":"Codon-specific development of pheochromocytoma in multiple endocrine neoplasia type 2","volume":"90","author":"Machens A","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"ref73","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1089\/thy.2008.0403","article-title":"Medullary thyroid cancer: management guidelines of the American Thyroid Association","volume":"19","author":"Kloos RT","year":"2009","journal-title":"Thyroid"},{"key":"ref74","doi-asserted-by":"crossref","first-page":"2520","DOI":"10.1007\/s00268-008-9734-2","article-title":"Pheochromocytoma in MEN 2A syndrome. Study of 54 patients","volume":"32","author":"Rodriguez JM","year":"2008","journal-title":"World J Surg"},{"key":"ref75","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1001\/jama.287.11.1427","article-title":"Biochemical diagnosis of pheochromocytoma: which test is best?","volume":"287","author":"Lenders JW","year":"2002","journal-title":"JAMA"},{"key":"ref76","doi-asserted-by":"crossref","first-page":"4602","DOI":"10.1210\/jc.2005-2668","article-title":"Comparison of diagnostic accuracy of urinary free metanephrines, vanillyl mandelic Acid, and catecholamines and plasma catecholamines for diagnosis of pheochromocytoma","volume":"92","author":"Boyle JG","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"ref77","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1210\/jc.2002-021251","article-title":"A comparison of biochemical tests for pheochromocytoma: measurement of fractionated plasma metanephrines compared with the combination of 24-hour urinary metanephrines and catecholamines","volume":"88","author":"Sawka AM","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"ref78","doi-asserted-by":"crossref","first-page":"2656","DOI":"10.1210\/jc.2002-030005","article-title":"Biochemical diagnosis of pheochromocytoma: how to distinguish true- from false-positive test results","volume":"88","author":"Eisenhofer G","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"ref79","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/j.1365-2796.2004.01425.x","article-title":"Biochemical diagnosis, localization and management of pheochromocytoma: focus on multiple endocrine neoplasia type 2 in relation to other hereditary syndromes and sporadic forms of the tumour","volume":"257","author":"Pacak K","year":"2005","journal-title":"J Intern Med"},{"key":"ref80","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1046\/j.1365-2265.1998.3751208.x","article-title":"Differences between sporadic and multiple endocrine neoplasia type 2A phaeochromocytoma","volume":"48","author":"Pomares FJ","year":"1998","journal-title":"Clin Endocrinol"},{"key":"ref81","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1210\/jc.2004-1627","article-title":"Clinical utility of noncontrast computed tomography attenuation value (hounsfield units) to differentiate adrenal adenomas\/hyperplasias from nonadenomas: Cleveland Clinic experience","volume":"90","author":"Hamrahian AH","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"ref82","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1148\/radiol.2342031876","article-title":"Adrenocortical carcinomas and adrenal pheochromocytomas: mass and enhancement loss evaluation at delayed contrast-enhanced CT","volume":"234","author":"Szolar DH","year":"2005","journal-title":"Radiology"},{"key":"ref83","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1148\/radiology.217.3.r00dc29798","article-title":"Characterization of indeterminate (lipid-poor) adrenal masses: use of washout characteristics at contrast-enhanced CT","volume":"217","author":"Pena CS","year":"2000","journal-title":"Radiology"},{"key":"ref84","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1089\/thy.2005.15.531","article-title":"RET proto-oncogene: a review and update of genotype-phenotype correlations in hereditary medullary thyroid cancer and associated endocrine tumors","volume":"15","author":"Kouvaraki MA","year":"2005","journal-title":"Thyroid"},{"issue":"2","key":"ref85","first-page":"487","article-title":"Risk and penetrance of primary hyperparathyroidism in multiple endocrine neoplasia type 2A families with mutations at codon 634 of the RET proto-oncogene. Groupe D\u2019etude des Tumeurs \u00e0 Calcitonine","volume":"83","author":"Schuffenecker I","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"key":"ref86","doi-asserted-by":"crossref","first-page":"221","DOI":"10.3390\/ijms13010221","article-title":"Molecular basis of medullary thyroid carcinoma: the role of RET polymorphisms","volume":"13","author":"Ceolin L","year":"2012","journal-title":"Int J Mol Sci"},{"key":"ref87","first-page":"1104","article-title":"Genotype-phenotype correlations in hereditary medullary thyroid carcinoma: oncological features and biochemical properties","volume":"86","author":"Machens A","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"ref88","first-page":"1736s","article-title":"The phenotypes associated with RET mutations in the multiple endocrine neoplasia type 2 syndrome","volume":"59","author":"Ponder BA","year":"1999","journal-title":"Cancer Res"},{"key":"ref89","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1056\/NEJM199409293311302","article-title":"Clinical screening as compared with DNA analysis in families with multiple endocrine neoplasia type 2A","volume":"331","author":"Lips CJ","year":"1994","journal-title":"N Engl J Med"},{"key":"ref90","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1055\/s-2002-26712","article-title":"Molecular and biochemical screening for the diagnosis and management of medullary thyroid carcinoma in multiple endocrine neoplasia type 2A","volume":"34","author":"Vieira AE","year":"2002","journal-title":"Horm Metab Res"},{"key":"ref91","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/S0039-6060(05)80120-5","article-title":"Presymptomatic DNA screening in families with multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma","volume":"118","author":"Frilling A","year":"1995","journal-title":"Surgery"},{"key":"ref92","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1001\/jama.1996.03540190047028","article-title":"The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis","volume":"276","author":"Eng C","year":"1996","journal-title":"JAMA"},{"key":"ref93","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.surg.2006.03.025","article-title":"Mutation analysis of the RET proto-oncogene and early thyroidectomy: results of a Portuguese cancer centre","volume":"141","author":"Bugalho MJ","year":"2007","journal-title":"Surgery"},{"key":"ref94","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1200\/JCO.2001.19.5.1374","article-title":"Estimation of risk of inherited medullary thyroid carcinoma in apparent sporadic patients","volume":"19","author":"Wiench M","year":"2001","journal-title":"J Clin Oncol"},{"key":"ref95","doi-asserted-by":"crossref","first-page":"4725","DOI":"10.1210\/jc.2007-1005","article-title":"RET genetic screening in patients with medullary thyroid cancer and their relatives: experience with 807 individuals at one center","volume":"92","author":"Elisei R","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"ref96","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/j.1365-2265.2010.03900.x","article-title":"RET genetic screening of sporadic medullary thyroid cancer (MTC) allows the preclinical diagnosis of unsuspected gene carriers and the identification of a relevant percentage of hidden familial MTC (FMTC)","volume":"74","author":"Romei C","year":"2011","journal-title":"Clin Endocrinol"},{"key":"ref97","series-title":"Carcinoma medular de tireoide: diagn\u00f3stico. Diretrizes Cl\u00ednicas na Sa\u00fade Suplementar da Associa\u00e7\u00e3o M\u00e9dica Brasileira e Ag\u00eancia Nacional de Sa\u00fade Suplementar 2011","author":"Maia AL","year":"2014"},{"key":"ref98","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1159\/000346174","article-title":"2012 European thyroid association guidelines for genetic testing and its clinical consequences in medullary thyroid cancer","volume":"1","author":"Elisei R","year":"2013","journal-title":"Eur Thyroid J"},{"key":"ref99","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1007\/s00464-005-0642-3","article-title":"Video-assisted central compartment lymphadenectomy in a patient with a positive RET oncogene: initial experience","volume":"21","author":"Miccoli P","year":"2007","journal-title":"Surg Endosc"},{"key":"ref100","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1089\/thy.2007.0414","article-title":"Clinical and oncological features of children and young adults with multiple endocrine neoplasia type 2A","volume":"18","author":"Punales MK","year":"2008","journal-title":"Thyroid"},{"key":"ref101","doi-asserted-by":"crossref","first-page":"E286","DOI":"10.1210\/jc.2013-3343","article-title":"Progression of medullary thyroid cancer in RET carriers of ATA class A and C mutations","volume":"99","author":"Machens A","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"ref102","doi-asserted-by":"crossref","first-page":"2644","DOI":"10.1210\/jc.2002-021422","article-title":"RET codon 634 mutations in multiple endocrine neoplasia type 2: variable clinical features and clinical outcome","volume":"88","author":"Punales MK","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"ref103","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1677\/ERC-08-0105","article-title":"Age-related neoplastic risk profiles and penetrance estimations in multiple endocrine neoplasia type 2A caused by germ line RET Cys634Trp (TGC>TGG) mutation","volume":"15","author":"Milos IN","year":"2008","journal-title":"Endocr Relat Cancer"},{"key":"ref104","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.ejso.2006.10.021","article-title":"Natural history, diagnosis, treatment and outcome of medullary thyroid cancer: 37 years experience on 157 patients","volume":"33","author":"Pelizzo MR","year":"2007","journal-title":"Eur J Surg Oncol"},{"key":"ref105","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1530\/EJE-14-0084","article-title":"Role of ret genetic variants in MEN 2-associated pheochromocytoma","volume":"170","author":"Siqueira DR","year":"2014","journal-title":"Eur J Endocrinol"},{"key":"ref106","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/j.1365-2265.1989.tb03727.x","article-title":"Hereditary localized pruritus in affected members of a kindred with multiple endocrine neoplasia type 2A (Sipple\u2019s syndrome)","volume":"30","author":"Nunziata V","year":"1989","journal-title":"Clin Endocrinol"},{"key":"ref107","doi-asserted-by":"crossref","first-page":"802","DOI":"10.7326\/0003-4819-111-10-802","article-title":"Multiple endocrine neoplasia type 2a associated with cutaneous lichen amyloidosis","volume":"111","author":"Gagel RF","year":"1989","journal-title":"Ann Intern Med"},{"issue":"2","key":"ref108","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s00383-011-2993-2","article-title":"Hirschsprung\u2019s disease and medullary thyroid carcinoma: 15-year experience with molecular genetic screening of the RET proto-oncogene","volume":"28","author":"Vaclavikova E","year":"2012","journal-title":"Pediatr Surg Int"},{"key":"ref109","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1046\/j.1365-2796.1998.00332.x","article-title":"Association of multiple endocrine neoplasia type 2 and Hirschsprung disease","volume":"243","author":"Romeo G","year":"1998","journal-title":"J Intern Med"},{"key":"ref110","doi-asserted-by":"crossref","first-page":"5658","DOI":"10.1210\/jcem.86.12.8070","article-title":"Guidelines for diagnosis and therapy of MEN type 1 and type 2","volume":"86","author":"Brandi ML","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"ref111","doi-asserted-by":"crossref","first-page":"E336","DOI":"10.1210\/jc.2012-3192","article-title":"Peak incidence of pheochromocytoma and primary hyperparathyroidism in multiple endocrine neoplasia 2: need for age-adjusted biochemical screening","volume":"98","author":"Machens A","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"ref112","article-title":"Genetic and clinical features of multiple endocrine neoplasia types 1 and 2","author":"Romei C","year":"2012","journal-title":"J Oncol"},{"key":"ref113","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0022-3468(96)90343-7","article-title":"Medullary thyroid carcinoma in children with multiple endocrine neoplasia types 2A and 2B","volume":"31","author":"Skinner MA","year":"1996","journal-title":"J Pediatr Surg"},{"key":"ref114","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.surg.2007.09.013","article-title":"Pheochromocytoma penetrance varies by RET mutation in MEN 2A","volume":"142","author":"Quayle FJ","year":"2007","journal-title":"Surgery"},{"key":"ref115","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1007\/s002689900123","article-title":"Primary hyperparathyroidism in multiple endocrine neoplasia type IIa: retrospective French multicentric study. Groupe d\u2019Etude des Tumeurs a Calcitonine (GETC, French Calcitonin Tumors Study Group), French Association of Endocrine Surgeons","volume":"20","author":"Kraimps JL","year":"1996","journal-title":"World J Surg"},{"key":"ref116","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/j.1365-2796.1995.tb01212.x","article-title":"Primary hyperparathyroidism in multiple endocrine neoplasia type 2A","volume":"238","author":"Raue F","year":"1995","journal-title":"J Intern Med"},{"key":"ref117","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1089\/thy.2010.0336","article-title":"Primary hyperparathyroidism as the first clinical manifestation of multiple endocrine neoplasia type 2A in a 5-year-old child","volume":"21","author":"Magalhaes PK","year":"2011","journal-title":"Thyroid"},{"key":"ref118","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.surg.2005.06.018","article-title":"Contralateral cervical and mediastinal lymph node metastasis in medullary thyroid cancer: systemic disease?","volume":"139","author":"Machens A","year":"2006","journal-title":"Surgery"},{"key":"ref119","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/s00595-007-3664-8","article-title":"Skip metastases in medullary thyroid carcinoma: a single-center experience","volume":"38","author":"Tavares MR","year":"2008","journal-title":"Surg Today"},{"key":"ref120","first-page":"395","article-title":"Surgical strategy for the treatment of sporadic medullary thyroid carcinoma: our experience","volume":"33","author":"Lupone G","year":"2012","journal-title":"G Chir"},{"key":"ref121","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1067\/msy.2001.118380a","article-title":"Impact of modified radical neck dissection on biochemical cure in medullary thyroid carcinomas","volume":"130","author":"Weber T","year":"2001","journal-title":"Surgery"},{"key":"ref122","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1007\/s00268-007-9185-1","article-title":"Increased risk of lymph node metastasis in multifocal hereditary and sporadic medullary thyroid cancer","volume":"31","author":"Machens A","year":"2007","journal-title":"World J Surg"},{"key":"ref123","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1097\/CCO.0b013e328359ff1f","article-title":"Surgical management of the lateral neck compartment for metastatic thyroid cancer","volume":"25","author":"Dralle H","year":"2013","journal-title":"Curr Opin Oncol"},{"key":"ref124","series-title":"AJCC Cancer Staging Manual","author":"Greene FL","year":"2003","edition":"6"},{"key":"ref125","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1046\/j.1365-2265.2001.01339.x","article-title":"Complete surgical lymph node resection does not prevent authentic recurrences of medullary thyroid carcinoma","volume":"55","author":"Franc S","year":"2001","journal-title":"Clin Endocrinol"},{"key":"ref126","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1007\/s00268-008-9795-2","article-title":"Alternative surgical strategies and favorable outcomes in patients with medullary thyroid carcinoma in Japan: experience of a single institution","volume":"33","author":"Ito Y","year":"2009","journal-title":"World J Surg"},{"key":"ref127","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1210\/jc.2011-2534","article-title":"Biological relevance of medullary thyroid microcarcinoma","volume":"97","author":"Machens A","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"ref128","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1001\/archsurg.1983.01390050017003","article-title":"Primary hyperparathyroidism in patients with multiple endocrine neoplasia syndromes. Surgical experience","volume":"118","author":"van Heerden JA","year":"1983","journal-title":"Arch Surg"},{"key":"ref129","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1016\/S0039-6060(96)80042-0","article-title":"Surgical management of hyperparathyroidism in patients with multiple endocrine neoplasia type 2A","volume":"120","author":"Herfarth KK","year":"1996","journal-title":"Surgery"},{"key":"ref130","doi-asserted-by":"crossref","first-page":"7","DOI":"10.4158\/EP10050.OR","article-title":"Evolution of surgical treatment of primary hyperparathyroidism in patients with multiple endocrine neoplasia type 2A","volume":"17","author":"Scholten A","year":"2011","journal-title":"Endocr Pract"},{"key":"ref131","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1097\/00000658-199605000-00003","article-title":"Parathyroid autotransplantation during thyroidectomy. Results of long-term follow-up","volume":"223","author":"Olson JA","year":"1996","journal-title":"Ann Surg"},{"key":"ref132","doi-asserted-by":"crossref","first-page":"2766","DOI":"10.1210\/jc.2008-2640","article-title":"Cinacalcet reduces serum calcium concentrations in patients with intractable primary hyperparathyroidism","volume":"94","author":"Marcocci C","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"ref133","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1097\/MPA.0b013e31828e34a4","article-title":"Consensus guidelines for the management and treatment of neuroendocrine tumors","volume":"42","author":"Kunz PL","year":"2013","journal-title":"Pancreas"},{"key":"ref134","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1056\/NEJMoa043999","article-title":"Prophylactic thyroidectomy in multiple endocrine neoplasia type 2A","volume":"353","author":"Skinner MA","year":"2005","journal-title":"N Engl J Med"},{"key":"ref135","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/S1015-9584(09)60141-X","article-title":"Initial lymph node dissection increases cure rates in patients with medullary thyroid cancer","volume":"30","author":"Greenblatt DY","year":"2007","journal-title":"Asian J Surg"},{"key":"ref136","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1002\/(SICI)1097-0142(20000415)88:8<1909::AID-CNCR21>3.0.CO;2-A","article-title":"Improved prediction of calcitonin normalization in medullary thyroid carcinoma patients by quantitative lymph node analysis","volume":"88","author":"Machens A","year":"2000","journal-title":"Cancer"},{"key":"ref137","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.oraloncology.2013.03.443","article-title":"Risk stratification in medullary thyroid cancer: Moving beyond static anatomic staging","volume":"49","author":"Tuttle RM","year":"2013","journal-title":"Oral Oncol"},{"key":"ref138","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1007\/BF02473391","article-title":"Compartment-oriented microdissection of regional lymph nodes in medullary thyroid carcinoma","volume":"24","author":"Dralle H","year":"1994","journal-title":"Surg Today"},{"key":"ref139","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1002\/bjs.6075","article-title":"Prediction of lateral lymph node metastases in medullary thyroid cancer","volume":"95","author":"Machens A","year":"2008","journal-title":"Br J Surg"},{"key":"ref140","first-page":"39775","article-title":"The North American Neuroendocrine Tumor Society consensus guideline for the diagnosis and management of neuroendocrine tumors: Pheochromocytoma, paraganglioma, and medullary thyroid cancer","author":"Chen H","year":"2010","journal-title":"Pancreas"},{"key":"ref141","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/S1470-2045(14)70154-8","article-title":"Outcomes of adrenal-sparing surgery or total adrenalectomy in phaeochromocytoma associated with multiple endocrine neoplasia type 2: an international retrospective population-based study","volume":"15","author":"Castinetti F","year":"2014","journal-title":"Lancet Oncol"},{"key":"ref142","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1002\/1097-0142(197903)43:3<825::AID-CNCR2820430308>3.0.CO;2-Q","article-title":"Medullary thyroid carcinoma: importance of serial serum calcitonin measurement","volume":"43","author":"Stepanas AV","year":"1979","journal-title":"Cancer"},{"key":"ref143","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1177\/172460089400900104","article-title":"Disappearance rate of serum calcitonin after total thyroidectomy for medullary thyroid carcinoma","volume":"9","author":"Fugazzola L","year":"1994","journal-title":"Int J Biol Markers"},{"key":"ref144","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/S0039-6060(96)80210-8","article-title":"Progression of postoperative residual medullary thyroid carcinoma as monitored by plasma calcitonin levels","volume":"119","author":"Tisell LE","year":"1996","journal-title":"Surgery"},{"key":"ref145","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1677\/erc.0.0110357","article-title":"Postoperative calcitonin study in medullary thyroid carcinoma","volume":"11","author":"Ismailov SI","year":"2004","journal-title":"Endocr Relat Cancer"},{"key":"ref146","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0026-0495(00)90663-2","article-title":"Increased circulating calcitonin in cirrhosis. Relation to severity of disease and calcitonin gene-related peptide","volume":"49","author":"Henriksen JH","year":"2000","journal-title":"Metabolism"},{"key":"ref147","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1056\/NEJM198101293040505","article-title":"Calcitonin: physiology and pathophysiology","volume":"304","author":"Austin LA","year":"1981","journal-title":"N Engl J Med"},{"key":"ref148","first-page":"264","article-title":"Frequency and significance of cervicomediastinal lymph node metastases in medullary thyroid carcinoma: results of a compartment-oriented microdissection method","volume":"40","author":"Dralle H","year":"1992","journal-title":"Henry Ford Hosp Med J"},{"key":"ref149","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1002\/1097-0142(19840115)53:2<278::AID-CNCR2820530216>3.0.CO;2-Z","article-title":"Nonparallel patterns of calcitonin and carcinoembryonic antigen levels in the follow-up of medullary thyroid carcinoma","volume":"53","author":"Busnardo B","year":"1984","journal-title":"Cancer"},{"key":"ref150","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1677\/ERC-07-0128","article-title":"Clinically unpredictable prognostic factors in the outcome of medullary thyroid cancer","volume":"14","author":"Miccoli P","year":"2007","journal-title":"Endocr Relat Cancer"},{"key":"ref151","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1089\/105072501750362709","article-title":"Prognostic factors in well-differentiated follicular-derived carcinoma and medullary thyroid carcinoma","volume":"11","author":"Baloch ZW","year":"2001","journal-title":"Thyroid"},{"key":"ref152","doi-asserted-by":"crossref","DOI":"10.1186\/1756-6614-3-10","article-title":"The prognostic value of tumor markers doubling times in medullary thyroid carcinoma - preliminary report","volume":"3","author":"Gawlik T","year":"2010","journal-title":"Thyroid Res"},{"key":"ref153","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1046\/j.1365-2265.1998.00392.x","article-title":"Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma: results in 899 patients. The GETC Study Group. Groupe d\u2019etude des tumeurs a calcitonine","volume":"48","author":"Modigliani E","year":"1998","journal-title":"Clin Endocrinol"},{"key":"ref154","first-page":"251","article-title":"Medullary thyroid carcinoma in Hong Kong Chinese patients","volume":"11","author":"Chow SM","year":"2005","journal-title":"Hong Kong Med J"},{"key":"ref155","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.1245\/s10434-009-0595-1","article-title":"Micromedullary thyroid cancer: how micro is truly micro?","volume":"16","author":"Pillarisetty VG","year":"2009","journal-title":"Ann Surg Oncol"},{"key":"ref156","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s12094-006-0198-2","article-title":"Medullary thyroid carcinoma: multivariate analysis of prognostic factors influencing survival","volume":"8","author":"Peixoto Callejo I","year":"2006","journal-title":"Clin Transl Oncol"},{"key":"ref157","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1097\/00000658-198404000-00014","article-title":"Relation of doubling time of plasma calcitonin levels to prognosis and recurrence of medullary thyroid carcinoma","volume":"199","author":"Miyauchi A","year":"1984","journal-title":"Ann Surg"},{"key":"ref158","doi-asserted-by":"crossref","first-page":"6077","DOI":"10.1210\/jc.2005-0044","article-title":"Prognostic impact of serum calcitonin and carcinoembryonic antigen doubling-times in patients with medullary thyroid carcinoma","volume":"90","author":"Barbet J","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"ref159","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1111\/j.1365-2265.2009.03666.x","article-title":"Calcitonin and carcinoembryonic antigen doubling times as prognostic factors in medullary thyroid carcinoma: a structured meta-analysis","volume":"72","author":"Meijer JA","year":"2010","journal-title":"Clin Endocrinol"},{"key":"ref160","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1089\/105072503768499716","article-title":"Calcitonin precursor levels in human medullary thyroid carcinoma","volume":"13","author":"Bihan H","year":"2003","journal-title":"Thyroid"},{"key":"ref161","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/cncr.24738","article-title":"Procalcitonin levels predict clinical course and progression-free survival in patients with medullary thyroid cancer","volume":"116","author":"Walter MA","year":"2010","journal-title":"Cancer"},{"key":"ref162","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1097\/SLA.0b013e31813e66b9","article-title":"Long-term clinical and biochemical follow-up in medullary thyroid carcinoma: a single institution\u2019s experience over 20 years","volume":"246","author":"Cupisti K","year":"2007","journal-title":"Ann Surg"},{"key":"ref163","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1111\/j.1365-2265.2008.03229.x","article-title":"Long-term prognosis of medullary thyroid carcinoma","volume":"69","author":"Rendl G","year":"2008","journal-title":"Clin Endocrinol"},{"key":"ref164","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1089\/thy.2010.0178","article-title":"Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system","volume":"20","author":"Tuttle RM","year":"2010","journal-title":"Thyroid"},{"key":"ref165","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1530\/EJE-07-0667","article-title":"Progression of medullary thyroid carcinoma: assessment with calcitonin and carcinoembryonic antigen doubling times","volume":"158","author":"Laure Giraudet A","year":"2008","journal-title":"Eur J Endocrinol"},{"key":"ref166","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1590\/S0004-27302007000500020","article-title":"Surgical approach to medullary thyroid cancer","volume":"51","author":"Lundgren CI","year":"2007","journal-title":"Arq Bras Endocrinol Metabol"},{"key":"ref167","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1210\/jc.2004-1500","article-title":"High frequency of bone\/bone marrow involvement in advanced medullary thyroid cancer","volume":"90","author":"Mirallie E","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"ref168","doi-asserted-by":"crossref","first-page":"524","DOI":"10.2967\/jnumed.107.047720","article-title":"18F-dihydroxyphenylalanine PET in patients with biochemical evidence of medullary thyroid cancer: relation to tumor differentiation","volume":"49","author":"Koopmans KP","year":"2008","journal-title":"J Nucl Med"},{"key":"ref169","first-page":"66","article-title":"18F-FDG PET detection of lymph node metastases in medullary thyroid carcinoma","volume":"43","author":"Szakall S","year":"2002","journal-title":"J Nucl Med"},{"issue":"28","key":"ref170","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1007\/s002590100614","article-title":"Fluorine-18 fluorodeoxyglucose positron emission tomography in medullary thyroid cancer: results of a multicentre study","author":"Diehl M","year":"2001","journal-title":"Eur J Nucl Med"},{"key":"ref171","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1007\/s00259-007-0425-2","article-title":"Diagnostic impact of PET with 18F-FDG, 18F-DOPA and 3-O-methyl-6-[18F]fluoro-DOPA in recurrent or metastatic medullary thyroid carcinoma","volume":"34","author":"Beuthien-Baumann B","year":"2007","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref172","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1677\/ERC-08-0152","article-title":"Secretive and proliferative tumor profile helps to select the best imaging technique to identify postoperative persistent or relapsing medullary thyroid cancer","volume":"16","author":"Faggiano A","year":"2009","journal-title":"Endocr Relat Cancer"},{"key":"ref173","first-page":"261","article-title":"Evaluation of efficacy and clinical impact of 18F-FDG-PET in the diagnosis of recurrent medullary thyroid cancer with increased calcitonin and negative imaging test","volume":"31","author":"Gomez-Camarero P","year":"2012","journal-title":"Rev Esp Med Nucl Imagen Mol"},{"key":"ref174","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1007\/s00259-011-2031-6","article-title":"Comparison of 18F-DOPA, 18F-FDG and 68Ga-somatostatin analogue PET\/CT in patients with recurrent medullary thyroid carcinoma","volume":"39","author":"Treglia G","year":"2012","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref175","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1097\/MNM.0b013e3283541157","article-title":"Prospective evaluation of 68Ga-DOTA-NOC PET-CT in patients with recurrent medullary thyroid carcinoma: comparison with 18F-FDG PET-CT","volume":"33","author":"Naswa N","year":"2012","journal-title":"Nucl Med Commun"},{"key":"ref176","first-page":"1890","article-title":"Improved diagnostic methods in the follow-up of medullary thyroid carcinoma by highly specific calcitonin measurements","volume":"85","author":"Engelbach M","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"ref177","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1089\/thy.2000.10.919","article-title":"Normal preoperative calcitonin levels do not always exclude medullary thyroid carcinoma in patients with large palpable thyroid masses","volume":"10","author":"Redding AH","year":"2000","journal-title":"Thyroid"},{"key":"ref178","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/00000658-197808000-00002","article-title":"Provocative agents and the diagnosis of medullary carcinoma of the thyroid gland","volume":"188","author":"Wells SA","year":"1978","journal-title":"Ann Surg"},{"key":"ref179","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1177\/107327480000700305","article-title":"Medullary carcinoma of the thyroid","volume":"7","author":"Randolph GW","year":"2000","journal-title":"Cancer Control"},{"key":"ref180","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S0039-6060(97)90217-8","article-title":"Reoperation in metastasizing medullary thyroid carcinoma: is a tumor stage-oriented approach justified?","volume":"122","author":"Gimm O","year":"1997","journal-title":"Surgery"},{"key":"ref181","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1001\/archsurg.135.8.895","article-title":"Long-term results of reoperation and localizing studies in patients with persistent or recurrent medullary thyroid cancer","volume":"135","author":"Kebebew E","year":"2000","journal-title":"Arch Surg"},{"key":"ref182","first-page":"60","article-title":"Reoperation in the treatment of asymptomatic metastasizing medullary thyroid carcinoma","volume":"99","author":"Tisell LE","year":"1986","journal-title":"Surgery"},{"key":"ref183","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1046\/j.1365-2796.1998.00333.x","article-title":"Surgical management of patients with persistent or recurrent medullary thyroid cancer","volume":"243","author":"Moley JF","year":"1998","journal-title":"J Intern Med"},{"key":"ref184","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1007\/s00268-007-9317-7","article-title":"Long-term outcome of reoperations for medullary thyroid carcinoma","volume":"32","author":"Fialkowski E","year":"2008","journal-title":"World J Surg"},{"key":"ref185","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1097\/00000658-199010000-00002","article-title":"Long-term course of patients with persistent hypercalcitoninemia after apparent curative primary surgery for medullary thyroid carcinoma","volume":"212","author":"van Heerden JA","year":"1990","journal-title":"Ann Surg"},{"key":"ref186","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1007\/s00268-006-0846-2","article-title":"Evidence-based approach to the management of sporadic medullary thyroid carcinoma","volume":"31","author":"Moley JF","year":"2007","journal-title":"World J Surg"},{"key":"ref187","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1002\/jso.20690","article-title":"Current approaches to medullary thyroid carcinoma, sporadic and familial","volume":"94","author":"Fialkowski EA","year":"2006","journal-title":"J Surg Oncol"},{"key":"ref188","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1038\/sj.bjc.6600930","article-title":"Long-term outcome of medullary thyroid carcinoma in patients with normal postoperative medical imaging","volume":"88","author":"Pellegriti G","year":"2003","journal-title":"Br J Cancer"},{"key":"ref189","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1677\/joe.0.1520275","article-title":"Regulatory peptides and other neuroendocrine markers in medullary carcinoma of the thyroid","volume":"152","author":"Hanna FW","year":"1997","journal-title":"J Endocrinol"},{"key":"ref190","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1046\/j.1365-2265.1997.3421147.x","article-title":"Metastatic parathyroid carcinoma in the MEN2A syndrome","volume":"47","author":"Jenkins PJ","year":"1997","journal-title":"Clin Endocrinol"},{"key":"ref191","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1136\/gut.29.4.537","article-title":"Pathophysiological study of diarrhoea in a patient with medullary thyroid carcinoma. Evidence against a secretory mechanism and for the role of shortened colonic transit time","volume":"29","author":"Rambaud JC","year":"1988","journal-title":"Gut"},{"key":"ref192","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/gut.20.7.629","article-title":"Role of calcitonin in diarrhoea associated with medullary carcinoma of the thyroid","volume":"20","author":"Cox TM","year":"1979","journal-title":"Gut"},{"key":"ref193","first-page":"549","article-title":"Somatostatin receptor expression in vivo and response to somatostatin analog therapy with or without other antineoplastic treatments in advanced medullary thyroid carcinoma","volume":"23","author":"Vainas I","year":"2004","journal-title":"J Exp Clin Cancer Res"},{"key":"ref194","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1210\/jc.2006-0334","article-title":"Selective activation of somatostatin receptor subtypes differentially modulates secretion and viability in human medullary thyroid carcinoma primary cultures: potential clinical perspectives","volume":"91","author":"Zatelli MC","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"ref195","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/j.1365-2265.1990.tb00490.x","article-title":"Long-term treatment of metastatic medullary thyroid carcinoma with the somatostatin analogue octreotide","volume":"33","author":"Mahler C","year":"1990","journal-title":"Clin Endocrinol"},{"key":"ref196","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.surg.2005.09.020","article-title":"Selective arterial chemoembolization for hepatic metastases from medullary thyroid carcinoma","volume":"138","author":"Lorenz K","year":"2005","journal-title":"Surgery"},{"key":"ref197","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1210\/jc.2005-2401","article-title":"Chemoembolization for liver metastases from medullary thyroid carcinoma","volume":"91","author":"Fromigue J","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"ref198","doi-asserted-by":"crossref","first-page":"4955","DOI":"10.1210\/jc.2004-2527","article-title":"Cushing\u2019s syndrome due to ectopic corticotropin secretion: twenty years\u2019 experience at the National Institutes of Health","volume":"90","author":"Ilias I","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"ref199","doi-asserted-by":"crossref","first-page":"4565","DOI":"10.1210\/jc.2002-021796","article-title":"Cushing\u2019s syndrome due to medullary thyroid carcinoma: diagnosis by proopiomelanocortin messenger ribonucleic acid in situ hybridization","volume":"88","author":"Smallridge RC","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"ref200","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1200\/JCO.1995.13.1.157","article-title":"Ketoconazole in the management of paraneoplastic Cushing\u2019s syndrome secondary to ectopic adrenocorticotropin production","volume":"13","author":"Winquist EW","year":"1995","journal-title":"J Clin Oncol"},{"issue":"6","key":"ref201","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1089\/thy.2013.0571","article-title":"Complete resolution of hypercortisolism with sorafenib in a patient with advanced medullary thyroid carcinoma and ectopic ACTH (adrenocorticotropic hormone) syndrome","volume":"24","author":"Barroso-Sousa R","year":"2014","journal-title":"Thyroid"},{"key":"ref202","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.ijrobp.2008.05.012","article-title":"Role of external beam radiotherapy in patients with advanced or recurrent nonanaplastic thyroid cancer: Memorial Sloan-kettering Cancer Center experience","volume":"73","author":"Terezakis SA","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref203","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1002\/hed.20791","article-title":"Postoperative radiotherapy for advanced medullary thyroid cancer--local disease control in the modern era","volume":"30","author":"Schwartz DL","year":"2008","journal-title":"Head Neck"},{"issue":"3","key":"ref204","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.semradonc.2012.03.010","article-title":"The role of external beam radiation and targeted therapy in thyroid cancer","volume":"22","author":"Brierley J","year":"2012","journal-title":"Semin Radiat Oncol"},{"issue":"6","key":"ref205","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1089\/thy.1996.6.305","article-title":"Medullary thyroid cancer: analyses of survival and prognostic factors and the role of radiation therapy in local control","author":"Brierley J","year":"1996","journal-title":"Thyroid"},{"issue":"11","key":"ref206","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1093\/jnci\/dji139","article-title":"Randomized trial of short- versus long-course radiotherapy for palliation of painful bone metastases","volume":"97","author":"Hartsell WF","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"ref207","first-page":"4259","article-title":"Percutaneous combined therapy for painful sternal metastases: a radiofrequency thermal ablation (RFTA) and cementoplasty protocol","volume":"27","author":"Masala S","year":"2007","journal-title":"Anticancer Res"},{"key":"ref208","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1054\/bjoc.2000.1314","article-title":"Treatment of advanced medullary thyroid cancer with an alternating combination of doxorubicin-streptozocin and 5 FU-dacarbazine. Groupe d\u2019Etude des Tumeurs a Calcitonine (GETC)","volume":"83","author":"Nocera M","year":"2000","journal-title":"Br J Cancer"},{"issue":"4","key":"ref209","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1097\/00000421-198808000-00015","article-title":"A phase II trial of streptozotocin and adriamycin in advanced APUD tumors","volume":"11","author":"Frame J","year":"1988","journal-title":"Am J Clin Oncol"},{"issue":"2","key":"ref210","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1002\/(SICI)1097-0142(19980715)83:2<372::AID-CNCR23>3.0.CO;2-P","article-title":"5-Fluorouracil, dacarbazine, and epirubicin in the treatment of patients with neuroendocrine tumors","volume":"15","author":"Bajetta E","year":"1998","journal-title":"Cancer"},{"key":"ref211","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/BF03346846","article-title":"Combined chemotherapy with bleomycin, adriamycin, and platinum in advanced thyroid cancer","volume":"14","author":"De Besi P","year":"1991","journal-title":"J Endocrinol Invest"},{"key":"ref212","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/bjc.1995.73","article-title":"Treatment of advanced medullary thyroid cancer with an alternating combination of 5 FU-streptozocin and 5 FU-dacarbazine. The Groupe d\u2019Etude des Tumeurs a Calcitonine (GETC)","volume":"71","author":"Schlumberger M","year":"1995","journal-title":"Br J Cancer"},{"key":"ref213","doi-asserted-by":"crossref","first-page":"4368","DOI":"10.1200\/JCO.2002.10.088","article-title":"Vascular permeability factor\/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy","volume":"20","author":"Dvorak HF","year":"2002","journal-title":"J Clin Oncol"},{"key":"ref214","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1210\/jc.2002-021863","article-title":"Clinical review 158: beyond radioiodine: a review of potential new therapeutic approaches for thyroid cancer","volume":"88","author":"Braga-Basaria M","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"ref215","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1089\/thy.2009.0417","article-title":"Increased expression of vascular endothelial growth factor and its receptors, VEGFR-1 and VEGFR-2, in medullary thyroid carcinoma","volume":"20","author":"Capp C","year":"2010","journal-title":"Thyroid"},{"key":"ref216","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1634\/theoncologist.5-suppl_1-3","article-title":"VEGF receptor signaling in tumor angiogenesis","volume":"5","author":"McMahon G","year":"2000","journal-title":"Oncologist"},{"key":"ref217","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1634\/theoncologist.9-suppl_1-2","article-title":"Vascular endothelial growth factor as a target for anticancer therapy","volume":"9","author":"Ferrara N","year":"2004","journal-title":"Oncologist"},{"key":"ref218","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1038\/sj.bjc.6602603","article-title":"ZD6474--a novel inhibitor of VEGFR and EGFR tyrosine kinase activity","volume":"92","author":"Ryan AJ","year":"2005","journal-title":"Br J Cancer"},{"key":"ref219","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse P","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"ref220","first-page":"7284","article-title":"ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases","volume":"62","author":"Carlomagno F","year":"2002","journal-title":"Cancer Res"},{"key":"ref221","first-page":"4645","article-title":"ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration","volume":"62","author":"Wedge SR","year":"2002","journal-title":"Cancer Res"},{"key":"ref222","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1200\/JCO.2011.35.5040","article-title":"Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial","volume":"30","author":"Wells SA","year":"2012","journal-title":"J Clin Oncol"},{"issue":"14","key":"ref223","doi-asserted-by":"crossref","first-page":"3722","DOI":"10.1158\/1078-0432.CCR-12-0411","article-title":"Vandetanib for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease: U.S. Food and Drug Administration drug approval summary","volume":"18","author":"Thornton K","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"6","key":"ref224","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.1210\/jc.2009-2461","article-title":"Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer","volume":"95","author":"Robinson BG","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"issue":"15","key":"ref225","doi-asserted-by":"crossref","first-page":"4239","DOI":"10.1158\/1078-0432.CCR-13-0071","article-title":"Vandetanib in children and adolescents with multiple endocrine neoplasia type 2B associated medullary thyroid carcinoma","volume":"19","author":"Fox E","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"3","key":"ref226","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1177\/1060028013512791","article-title":"Vandetanib for the treatment of medullary thyroid carcinoma","volume":"48","author":"Cooper MR","year":"2014","journal-title":"Ann Pharmacother"},{"key":"ref227","doi-asserted-by":"crossref","first-page":"6056","DOI":"10.1038\/sj.onc.1207810","article-title":"Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors","volume":"23","author":"Carlomagno F","year":"2004","journal-title":"Oncogene"},{"issue":"29","key":"ref228","doi-asserted-by":"crossref","first-page":"3639","DOI":"10.1200\/JCO.2012.48.4659","article-title":"Cabozantinib in progressive medullary thyroid cancer","volume":"31","author":"Elisei R","year":"2013","journal-title":"J Clin Oncol"},{"key":"ref229","first-page":"1","article-title":"Profile of cabozantinib and its potential in the treatment of advanced medullary thyroid cancer","volume":"6","author":"Hart CD","year":"2013","journal-title":"Onco Targets Ther"},{"key":"ref230","doi-asserted-by":"crossref","first-page":"8715","DOI":"10.1158\/0008-5472.CAN-05-4665","article-title":"AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts","volume":"66","author":"Polverino A","year":"2006","journal-title":"Cancer Res"},{"key":"ref231","doi-asserted-by":"crossref","first-page":"3794","DOI":"10.1200\/JCO.2008.18.7815","article-title":"Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer","volume":"27","author":"Schlumberger MJ","year":"2009","journal-title":"J Clin Oncol"},{"key":"ref232","doi-asserted-by":"crossref","first-page":"7099","DOI":"10.1158\/0008-5472.CAN-04-1443","article-title":"BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF\/MEK\/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis","volume":"64","author":"Wilhelm SM","year":"2004","journal-title":"Cancer Res"},{"key":"ref233","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1200\/JCO.2009.25.0068","article-title":"Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer","volume":"28","author":"Lam ET","year":"2010","journal-title":"J Clin Oncol"},{"key":"ref234","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1158\/1078-0432.CCR-10-2041","article-title":"Identification of soluble candidate biomarkers of therapeutic response to sunitinib in medullary thyroid carcinoma in preclinical models","volume":"17","author":"Broutin S","year":"2011","journal-title":"Clin Cancer Res"},{"key":"ref235","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1200\/JCO.2006.06.3602","article-title":"Sunitinib: from rational design to clinical efficacy","volume":"25","author":"Chow LQ","year":"2007","journal-title":"J Clin Oncol"},{"key":"ref236","doi-asserted-by":"crossref","first-page":"5260","DOI":"10.1158\/1078-0432.CCR-10-0994","article-title":"Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation","volume":"16","author":"Carr LL","year":"2010","journal-title":"Clin Cancer Res"},{"key":"ref237","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0002-9440(10)63273-7","article-title":"Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts","volume":"165","author":"Inai T","year":"2004","journal-title":"Am J Pathol"},{"key":"ref238","doi-asserted-by":"crossref","first-page":"4708","DOI":"10.1200\/JCO.2007.15.9566","article-title":"Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study","volume":"26","author":"Cohen EE","year":"2008","journal-title":"J Clin Oncol"},{"key":"ref239","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/j.surg.2005.10.019","article-title":"Cellular effects of imatinib on medullary thyroid cancer cells harboring multiple endocrine neoplasia Type 2A and 2B associated RET mutations","volume":"139","author":"de Groot JW","year":"2006","journal-title":"Surgery"},{"key":"ref240","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1530\/EJE-06-0695","article-title":"Efficacy of imatinib mesylate in advanced medullary thyroid carcinoma","volume":"157","author":"Frank-Raue K","year":"2007","journal-title":"Eur J Endocrinol"},{"key":"ref241","doi-asserted-by":"crossref","first-page":"3466","DOI":"10.1210\/jc.2007-0649","article-title":"A phase II trial of imatinib therapy for metastatic medullary thyroid carcinoma","volume":"92","author":"de Groot JW","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"ref242","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1089\/thy.2013.0571","article-title":"Complete resolution of hypercortisolism with sorafenib in a patient with advanced medullary thyroid carcinoma and ectopic ACTH syndrome","volume":"24","author":"Barroso-Sousa R","year":"2014","journal-title":"Thyroid"},{"key":"ref243","first-page":"57","article-title":"Advanced medullary thyroid cancer: pathophysiology and management","volume":"5","author":"Ferreira CV","year":"2013","journal-title":"Cancer Manag Res"},{"key":"ref244","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1200\/JCO.2009.23.6604","article-title":"Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer","volume":"28","author":"Wells SA","year":"2010","journal-title":"J Clin Oncol"},{"key":"ref245","doi-asserted-by":"crossref","first-page":"K51","DOI":"10.1530\/EJE-13-0015","article-title":"Toxic cardiomyopathy leading to fatal acute cardiac failure related to vandetanib: a case report with histopathological analysis","volume":"168","author":"Scheffel RS","year":"2013","journal-title":"Eur J Endocrinol"},{"key":"ref246","doi-asserted-by":"crossref","first-page":"2660","DOI":"10.1200\/JCO.2010.32.4145","article-title":"Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer","volume":"29","author":"Kurzrock R","year":"2011","journal-title":"J Clin Oncol"},{"key":"ref247","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1530\/EJE-11-0129","article-title":"Analysis of the efficacy and toxicity of sorafenib in thyroid cancer: a phase II study in a UK based population","volume":"165","author":"Ahmed M","year":"2011","journal-title":"Eur J Endocrinol"},{"key":"ref248","doi-asserted-by":"crossref","first-page":"3657","DOI":"10.1200\/JCO.2012.45.2938","article-title":"Late cardiac effects of cancer treatment","volume":"30","author":"Lenihan DJ","year":"2012","journal-title":"J Clin Oncol"},{"key":"ref249","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1089\/108497804773391694","article-title":"Receptor radionuclide therapy with 90Y-DOTATOC in patients with medullary thyroid carcinomas","volume":"19","author":"Bodei L","year":"2004","journal-title":"Cancer Biother Radiopharm"},{"key":"ref250","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1200\/JCO.2005.04.4917","article-title":"Survival improvement in patients with medullary thyroid carcinoma who undergo pretargeted anti-carcinoembryonic-antigen radioimmunotherapy: a collaborative study with the French Endocrine Tumor Group","volume":"24","author":"Chatal JF","year":"2006","journal-title":"J Clin Oncol"},{"key":"ref251","first-page":"129","article-title":"Thyroid carcinoma with bone metastases: a prognostic factor study","volume":"2","author":"Wu K","year":"2008","journal-title":"Clin Med Oncol"},{"key":"ref252","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1210\/jc.2012-1169","article-title":"Skeletal-related events due to bone metastases from differentiated thyroid cancer","volume":"97","author":"Farooki A","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"ref253","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1002\/(SICI)1097-0142(20000301)88:5<1082::AID-CNCR20>3.0.CO;2-Z","article-title":"Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials","volume":"88","author":"Lipton A","year":"2000","journal-title":"Cancer"},{"key":"ref254","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1054\/bjoc.2001.1832","article-title":"Pamidronate improves the quality of life and induces clinical remission of bone metastases in patients with thyroid cancer","volume":"84","author":"Vitale G","year":"2001","journal-title":"Br J Cancer"},{"key":"ref255","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.breast.2012.04.008","article-title":"Prolonged administration of bisphosphonates is well-tolerated and effective for skeletal-related events in Chinese breast cancer patients with bone metastasis","volume":"21","author":"Ding X","year":"2012","journal-title":"Breast"},{"key":"ref256","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1038\/bjc.2012.385","article-title":"Concomitant oral tyrosine kinase inhibitors and bisphosphonates in advanced renal cell carcinoma with bone metastases","volume":"107","author":"Beuselinck B","year":"2012","journal-title":"Br J Cancer"},{"key":"ref257","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1089\/thy.2010.0169","article-title":"Zoledronic acid in the treatment of bone metastases from differentiated thyroid carcinoma","volume":"21","author":"Orita Y","year":"2011","journal-title":"Thyroid"},{"issue":"6","key":"ref258","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1016\/j.surg.2010.09.014","article-title":"Laparoscopic radiofrequency thermal ablation of neuroendocrine hepatic metastases: long-term follow-up","volume":"148","author":"Akyildiz HY","year":"2010","journal-title":"Surgery"},{"issue":"1","key":"ref259","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.surg.2007.01.036","article-title":"Laparoscopic radiofrequency ablation of neuroendocrine liver metastases: a 10-year experience evaluating predictors of survival","volume":"142","author":"Mazzaglia PJ","year":"2007","journal-title":"Surgery"},{"key":"ref260","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1002\/ssu.10031","article-title":"Palliative therapy for lung cancer","volume":"21","author":"Bezjak A","year":"2003","journal-title":"Semin Surg Oncol"},{"key":"ref261","doi-asserted-by":"crossref","DOI":"10.1136\/bcr.09.2010.3301","article-title":"Brain metastasis from medullary thyroid carcinoma","author":"B\u00f6rcek P","year":"2010","journal-title":"BMJ Case Rep"},{"key":"ref262","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1002\/cncr.11488","article-title":"Management of brain metastases from thyroid carcinoma: a study of 16 pathologically confirmed cases over 25 years","volume":"98","author":"McWilliams RR","year":"2003","journal-title":"Cancer"},{"key":"ref263","doi-asserted-by":"crossref","first-page":"3637","DOI":"10.1210\/jcem.82.11.4386","article-title":"Prognosis and treatment of brain metastases in thyroid carcinoma","volume":"82","author":"Chiu AC","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"key":"ref264","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1111\/j.1445-2197.2006.03992.x","article-title":"Medullary thyroid carcinoma: a 20-year experience from a centre in South India","volume":"77","author":"Finny P","year":"2007","journal-title":"ANZ J Surg"}],"container-title":["Arquivos Brasileiros de Endocrinologia &amp; Metabologia"],"original-title":[],"link":[{"URL":"http:\/\/www.scielo.br\/pdf\/abem\/v58n7\/0004-2730-abem-58-7-0667.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,4]],"date-time":"2024-06-04T13:49:53Z","timestamp":1717508993000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S0004-27302014000700667&lng=pt&tlng=pt"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10]]},"references-count":264,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2014,10]]}},"alternative-id":["S0004-27302014000700667"],"URL":"https:\/\/doi.org\/10.1590\/0004-2730000003427","relation":{},"ISSN":["0004-2730"],"issn-type":[{"value":"0004-2730","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,10]]}}}